Vyleesi (Bremelanotide) in Adolescents Ages 12 to 17: What the Off-Label Evidence Actually Shows

What Is Bremelanotide and Who Is It Actually Approved For?

Bremelanotide is a melanocortin receptor agonist that acts centrally on MC3R and MC4R receptors to modulate sexual desire pathways in the brain. It is sold under the brand name Vyleesi and is administered as a 1.75 mg subcutaneous autoinjector taken approximately 45 minutes before anticipated sexual activity. The FDA approved bremelanotide in August 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal adult women only.

That word "adult" is doing a lot of work. The approval was based on two key Phase 3 trials, RECONNECT Study 1 and Study 2, which enrolled women aged 22 to 57. No participants were younger than 22. The indication has never been extended to adolescents, and no supplemental New Drug Application for a pediatric population has been filed with the FDA as of this writing.

What Bremelanotide Does in the Brain

The drug does not work like a hormone. It does not raise estrogen or testosterone. Instead, it acts on melanocortin pathways in the hypothalamus, areas that are still actively maturing through adolescence and into the early twenties. The hypothalamic-pituitary-gonadal (HPG) axis that governs puberty, menstrual cyclicity, and reproductive hormone output is in a dynamic, sensitive state during ages 12 to 17. Drugs that interact with central melanocortin receptors during this window carry theoretical risks to pubertal development that have simply never been studied.

How the RECONNECT Trials Defined HSDD

HSDD in the RECONNECT trials was defined using validated instruments including the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale-Desire (FSDS-D). In Study 1, bremelanotide increased the mean number of satisfying sexual events by 0.5 per month over placebo, and reduced distress scores modestly but statistically significantly. These effect sizes were measured in adult women with established HSDD, not in adolescents whose sexual desire patterns are still forming in the context of puberty, relationship experience, and psychosocial development.

Why Adolescents Are Categorically Excluded From the Evidence Base

There is no published peer-reviewed study of bremelanotide in any person under 18, of any sex. This is not a minor data gap. It is a complete absence.

The FDA Pediatric Research Equity Act and This Drug

Under the Pediatric Research Equity Act (PREA), the FDA may require pediatric studies for drugs that are likely to be used in children. PREA does not automatically require studies in adolescents for conditions, like adult HSDD, that the FDA does not consider relevant pediatric indications. Palatin Technologies, the manufacturer, received a waiver from pediatric study requirements because the condition the drug treats is not recognized as a pediatric condition. This is not a technicality. It reflects a genuine clinical and regulatory judgment that HSDD as defined in adults does not apply straightforwardly to adolescents.

Sexual Desire in Adolescence Is Not the Same Construct

Sexual desire in adolescent girls is shaped by puberty stage, hormonal flux, early relational experience, body image, anxiety, and social context in ways that are categorically different from the desire disorder construct in adult women. The American College of Obstetricians and Gynecologists (ACOG) recognizes that sexual concerns in younger women and adolescents require a developmental approach and thorough psychosocial assessment before any pharmacologic intervention is considered.

A teen reporting low sexual interest may be experiencing depression, anxiety, a history of sexual trauma, relationship difficulty, hormonal contraceptive side effects, thyroid dysfunction, an eating disorder, or simply a normal variation in libido. None of these causes are addressed by bremelanotide, and none were adequately screened for in the RECONNECT trials.

Safety Profile in Adults: What Would Translate to Adolescents (and What We Cannot Know)

Understanding the adult safety data is necessary, because any clinician considering off-label use in an adolescent would be extrapolating entirely from adult data.

Nausea and Vomiting

Nausea occurred in approximately 40% of women in the RECONNECT trials, making it by far the most common adverse effect. It was typically transient, peaking about one hour after injection and resolving within two hours. Severe nausea occurred in 13% of participants. In adolescents, who may already experience nausea from hormonal changes, stress, or concurrent medications (such as combined oral contraceptives), the additive burden is unknown.

Transient Blood Pressure Changes

Bremelanotide causes a transient decrease in blood pressure followed by a small increase. In adult trials, mean maximum decreases of approximately 6 mmHg in systolic and 3 mmHg in diastolic blood pressure were observed, with return to baseline within approximately 12 hours. For most healthy adults this is clinically inconsequential. In adolescents with undiagnosed cardiac conditions, autonomic instability, or eating disorders (which carry high rates of cardiovascular complications), the risk profile is unknown and potentially more serious.

Hyperpigmentation

Focal hyperpigmentation of the face, gums, and breasts has been reported with repeated dosing in adult women. The mechanism involves MC1R activity in melanocytes. Adolescent skin is not known to have differential vulnerability, but no data exist, and the psychological impact of hyperpigmentation may be greater in a young person than in an adult.

Central Nervous System and Developmental Concerns

This is the concern with the least data and the most theoretical weight. The melanocortin system is involved in energy regulation, stress response, and reproductive axis maturation. The MC3R and MC4R receptors targeted by bremelanotide are expressed in the hypothalamus during periods of active neuroendocrine development. Animal studies in rodents have shown that melanocortin system manipulation during early life can alter adult reproductive behavior and HPG axis set points. Direct extrapolation to human adolescents is not valid, but the theoretical signal is enough that no responsible clinician should dismiss it without evidence that it does not apply.

Pregnancy, Lactation, and Contraception: A Required Discussion for Any Adolescent Considering This Drug

Adolescent girls ages 12 to 17 who are sexually active may be pregnant or may become pregnant. This makes the pregnancy and lactation profile of bremelanotide directly relevant to this age group, arguably more so than to many adult populations.

Pregnancy Safety

Bremelanotide is contraindicated in pregnancy. The FDA label states that animal reproduction studies showed fetal harm at exposures below the recommended human dose. Specifically, rat studies showed increased embryofetal loss and reduced fetal weight. No adequate human pregnancy data exist.

The label instructs: perform a pregnancy test before initiating treatment, use effective contraception during treatment, and discontinue the drug immediately if pregnancy is confirmed. For an adolescent who may not have a regular menstrual cycle (due to normal pubertal variation, stress-related hypothalamic amenorrhea, or polycystic ovary syndrome), confirming non-pregnant status before each use is a real logistical and compliance challenge.

Lactation

No data exist on the presence of bremelanotide in human breast milk, its effects on the breastfed infant, or its effects on milk production. The FDA label advises against use in breastfeeding women. For adolescents who may be postpartum (teen pregnancy rates, while declining, remain a clinical reality), this prohibition is directly applicable.

Contraception Requirements

Any adolescent using bremelanotide off-label would need reliable contraception, both because of fetal risk and because unintended pregnancy is already disproportionately prevalent in the 15 to 19 age group. The CDC reports that approximately 15.4 per 1,000 women aged 15 to 19 became pregnant in 2019, the latest year for which full estimates are available. Initiating a drug that requires reliable contraception and pregnancy testing before each use adds a layer of medical complexity that must be explicitly addressed before any prescribing decision.

How This Drug Interacts With Conditions Common in Adolescent Girls

PCOS

Polycystic ovary syndrome affects approximately 6 to 12% of reproductive-age women and is frequently first diagnosed in adolescence. PCOS is associated with irregular cycles, elevated androgens, and, in some teens, reduced sexual self-esteem related to body image. Reduced sexual desire in a teen with PCOS is more likely to stem from depression, body dissatisfaction, or hormonal imbalance than from a primary central desire disorder responsive to bremelanotide. No PCOS-specific data on bremelanotide exist.

Depression and Anxiety

Depression affects roughly 20% of adolescent girls at some point during this developmental period. Low libido is a core symptom of depression. Bremelanotide does not treat depression and has not been studied in people with active major depressive disorder. Using it to address libido in an adolescent with undiagnosed or undertreated depression would likely be ineffective and could delay appropriate care.

Hormonal Contraceptive Use

Many adolescent girls who are sexually active use combined oral contraceptives, the hormonal IUD, or the implant. Hormonal contraceptives are a recognized cause of reduced sexual desire in some women, likely through testosterone-lowering and sex hormone-binding globulin-raising mechanisms. If an adolescent reports low libido, assessing and potentially switching her contraceptive method is a logical, evidence-informed, safe first step. Reaching for bremelanotide before addressing this is not defensible clinical practice.

Thyroid Dysfunction

Hypothyroidism causes fatigue and reduced sexual interest and is more common in young women than in men of the same age. ACOG recommends evaluation for thyroid dysfunction as part of the workup for menstrual irregularity and associated symptoms in adolescents. Treating low libido in a teen without first checking thyroid function is an incomplete evaluation.

Who This Is Right For and Not Right For: A Life-Stage Breakdown

The following framework is intended to help clinicians and patients understand where bremelanotide fits, and explicitly where it does not.

Not appropriate: Adolescents ages 12 to 17 (any indication)

Bremelanotide has no evidence base in this age group. The theoretical risks from melanocortin receptor agonism during active HPG axis and hypothalamic development, combined with zero safety data, mean the benefit-to-risk ratio cannot be calculated and is almost certainly unfavorable for any adolescent patient. No guideline from ACOG, ASRM, or The Menopause Society supports this use.

A sexual health concern in a 12 to 17-year-old girl warrants:

• Comprehensive psychosocial assessment including screening for trauma and depression
• Review of current medications (especially hormonal contraceptives and SSRIs)
• Thyroid function testing and basic hormone panel (FSH, LH, free testosterone, SHBG)
• Referral to a pediatric gynecologist or adolescent medicine specialist with sexual health training
• Sex therapy or trauma-informed psychotherapy as appropriate

Appropriate: Premenopausal adult women (18 and older) with confirmed HSDD

Bremelanotide is a reasonable option for adult premenopausal women who have been properly diagnosed with HSDD, screened for treatable secondary causes, and counseled about the modest effect size and nausea burden. As the RECONNECT trial authors noted, "bremelanotide significantly improved sexual desire and reduced distress associated with low sexual desire" in a population whose mean age was approximately 38 years.

Perimenopausal and menopausal women

Bremelanotide is not FDA-approved for perimenopausal or postmenopausal women. The RECONNECT trials excluded postmenopausal participants. Some clinicians use it off-label in perimenopausal women, but this use is also extrapolated from adult premenopausal data. The hormonal environment of perimenopause, with falling estrogen and fluctuating progesterone, may alter both the drug's CNS effects and the clinical presentation of desire changes. No perimenopause-specific efficacy data have been published.

The Evidence Gap: Women Are Under-Represented, Adolescents Are Invisible

Women have been historically under-represented in clinical trials across medicine, and sexual health research is no exception. The NIH Revitalization Act of 1993 required inclusion of women in federally funded research, but adolescent girls with sexual health concerns remain largely invisible in trial populations.

The RECONNECT trials enrolled 1,267 women total across the two studies. All were adults. All were premenopausal by design. The youngest participant was 22 years old. Any claim that data from these women can be directly applied to a 14-year-old with low sexual interest would be scientifically unsound.

This is not a minor caveat. Sex-specific pharmacokinetics are well documented for many drugs, and age-related pharmacokinetic differences in adolescents are also established. Bremelanotide is metabolized primarily through peptide hydrolysis. Whether adolescent girls metabolize the drug faster, slower, or differently than adult women has never been studied. The FDA's guidance on pediatric pharmacokinetics explicitly acknowledges that weight-based dosing extrapolation from adults to adolescents is not always appropriate, particularly for drugs acting centrally.

What Clinicians and Parents Should Know: The Practical Bottom Line

If you are a clinician seeing an adolescent girl who reports low sexual desire, bremelanotide should not be on the differential of treatment options. Full stop.

If you are a parent who has read about Vyleesi and is wondering whether it could help your teenager, the answer the evidence supports is no, and the reasons are not bureaucratic. They are pharmacological, developmental, and safety-based.

If you are a teenager reading this yourself, please know that low or absent sexual interest during adolescence is common, often situational, and almost never caused by the kind of central neurochemical deficit that bremelanotide is designed to address. It is worth talking to a doctor or nurse practitioner, not to get a prescription for this drug, but to identify what is actually going on, whether that is depression, hormonal contraceptive side effects, thyroid dysfunction, or something relational that therapy can address far more effectively than any injection.

The Society for Adolescent Health and Medicine and ACOG both recommend that sexual health concerns in teens be addressed through developmental, trauma-informed, biopsychosocial frameworks. Pharmacology is rarely the first, second, or third tool.